Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Descriptor ID |
D000971
|
MeSH Number(s) |
E02.183.750.500 E02.319.077.500 E02.319.310.037
|
Concept/Terms |
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Combined Antineoplastic Agents
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Antineoplastic Combined Chemotherapy Regimens
- Drug Combinations, Antineoplastic
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
- Chemotherapy Protocols, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in this website by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 56 | 30 | 86 |
1995 | 64 | 22 | 86 |
1996 | 54 | 24 | 78 |
1997 | 62 | 16 | 78 |
1998 | 65 | 16 | 81 |
1999 | 77 | 21 | 98 |
2000 | 57 | 36 | 93 |
2001 | 61 | 31 | 92 |
2002 | 87 | 40 | 127 |
2003 | 115 | 52 | 167 |
2004 | 114 | 59 | 173 |
2005 | 106 | 50 | 156 |
2006 | 128 | 77 | 205 |
2007 | 134 | 55 | 189 |
2008 | 155 | 71 | 226 |
2009 | 134 | 73 | 207 |
2010 | 178 | 68 | 246 |
2011 | 169 | 71 | 240 |
2012 | 133 | 68 | 201 |
2013 | 172 | 65 | 237 |
2014 | 198 | 77 | 275 |
2015 | 188 | 92 | 280 |
2016 | 139 | 106 | 245 |
2017 | 173 | 88 | 261 |
2018 | 167 | 65 | 232 |
2019 | 191 | 78 | 269 |
2020 | 184 | 129 | 313 |
2021 | 155 | 120 | 275 |
2022 | 48 | 177 | 225 |
2023 | 11 | 199 | 210 |
2024 | 2 | 34 | 36 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Severe reactivation of seronegative occult hepatitis B after chemotherapy for lymphoma. Lancet. 2024 Apr 06; 403(10434):1372-1373.
-
HSR24-130: Real-World Outcomes in Patients With Burkitt Lymphoma in a Safety-Net Health System. J Natl Compr Canc Netw. 2024 Apr 05; 22(2.5).
-
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J. Clin Cancer Res. 2024 Apr 01; 30(7):1273-1280.
-
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study. Lancet Oncol. 2024 Apr; 25(4):488-500.
-
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2024 Apr; 11(4):e287-e298.
-
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study. Lancet Oncol. 2024 Apr; 25(4):474-487.
-
The MUC1-HIF-1a signaling axis regulates pancreatic cancer pathogenesis through polyamine metabolism remodeling. Proc Natl Acad Sci U S A. 2024 Apr 02; 121(14):e2315509121.
-
Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer. Oncotarget. 2024 Mar 19; 15:238-247.
-
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nat Commun. 2024 Mar 19; 15(1):2446.
-
Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study. Oral Oncol. 2024 Apr; 151:106747.